N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=301 A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Asthma
Primary: Change in FEV1 — -0.40; 0.69; -0.59 percentage of change
N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
Phase 3 N=465 Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
Asthma
Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 12 Weeks. — 0.134; 0.293; 0.262 Liter — p=0.0005
Phase 4 N=32 Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Asthma
Primary: Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID. — 0.37; 0.21 mm/wk
Phase 3 N=278 CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)
Asthma
Primary: Rate of Exacerbations Requiring Systemic Corticosteroids — 0.97; 0.95 events per years of follow-up
Phase 2 N=25 A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
Asthma
Primary: Safety: Relative Change From Baseline* in Forced Expiratory Volume in 1 s (FEV1) -- 15 Min Post-dose — 2.12; 0.26 percent change — p=0.113
Phase 4 N=257 Treatment Of Symptomatic Asthma In Children
Asthma
Primary: Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period — 50.45; 49.75 percentage of days — p=0.63
Phase 2 N=27 Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Asthma
Primary: Maximum Percent Drop From Pre-allergen Baseline in Forced Expiratory Volume in 1 Second (FEV1) for Late-Phase Asthma Response (LAR) at Screening — 27.19; 20.47 percent…
Phase 4 N=100 SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
Asthma
Primary: Number of Participants in Each Arm With a Need for an Increase in Study Medication — 29; 29 Participants
Phase 2 N=20 The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen
Asthma
Primary: Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1 — 90.97; 91.32; 87.28…
Phase 2 N=10 Oral Nadolol for the Treatment of Adults With Mild Asthma
Asthma
Primary: Mean Daily Dose at Study Termination Across Participants — 29.6 mg
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
Phase 1 N=27 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Asthma
Primary: Number of Participants Who Experienced One or More Adverse Events — 9; 3 Participants
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
Phase 3 N=47 Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)
Asthma, Exercise-Induced
Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction…
Phase 1 N=46 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
Asthma
Primary: Number of Participants Who Experienced At Least One Adverse Event — 2; 4; 6; 9 participants
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
Phase 4 N=191 Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
Asthma · Allergic Rhinitis
Primary: Change From Baseline for Daytime Asthma Symptom Score — 0.32; 0.16; 0.29; 0.13 Units on scale — p=0.015
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
Phase 3 N=1,162 Montelukast Back to School Asthma Study (0476-340)
Asthma
Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days
Phase 3 N=46 Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Asthma
Primary: Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge — 0.822; 6.468 Percent — p=0.0208
Phase 2 N=147 Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Asthma
Primary: Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period — -0.002; -0.001; -0.034; -0.031 Liters
N/A N=193 Specific Use-Result of Spiriva Respimat® in Asthmatics
Asthma
Primary: Number of Participants With Suspected Adverse Drug Reactions (ADRs) — 5 Participants
Phase 3 N=78 Study in Adult Patients With Moderate to Severe Asthma
Asthma
Primary: Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3 — 2.68; 1.63 score on a scale — p=0.385
Phase 1 N=16 Early Airway Response to Allergen in Asthmatics (MK-0000-176)
Asthma
Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001
Phase 2 N=174 Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
Asthma
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14) — 0.3196; 0.3076; 0.2795; 0.2726 Liters — p=<0.0001
Phase 3 N=210 Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
Asthma
Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 3 N=689 Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
Asthma
Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants